Clinical Trial

Study of LX2006 Gene Therapy in Friedreich Ataxia Cardiomyopathy

Name: Study of LX2006 Gene Therapy in Friedreich Ataxia Cardiomyopathy — clinical trial record (NCT07721025)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: SUNRISE-FA 2

Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

The purpose of Study LX2006-03, a multicenter, Phase 2, open-label, randomized, controlled study, is to evaluate the efficacy and safety of LX2006 gene therapy in participants with Friedreich ataxia (FA) cardiomyopathy (CM).

Trial Details

NCT Number	NCT07721025
Lead Sponsor	Lexeo Therapeutics
Conditions	Friedreich Ataxia, Cardiomyopathy, Secondary
Enrollment	26 participants
Start Date	2026-06-25
Primary Completion	2032-06 (estimated)
Study Completion	2032-06 (estimated)
Updated on ClinicalTrials.gov	2026-07-22